News

Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference

LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company will be presenting at the following conference:

02/05/2024

Are Medical Stocks Lagging Achilles Therapeutics (ACHL) This Year?

Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and HealthEquity (HQY) have performed compared to their sector so far this year.

09/22/2023

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Achilles Therapeutics plc (ACHL) a buy, sell, or hold?

Achilles Therapeutics plc (ACHL) can hold. Click on Rating Page for detail.

What is Achilles Therapeutics plc's stock price?

The price of Achilles Therapeutics plc (ACHL) is 0.76 and it was updated on 2024-04-27 07:00:38.

Is Achilles Therapeutics plc (ACHL) overvalued or undervalued?

Currently Achilles Therapeutics plc (ACHL) is in undervalued.

News

From:

To:

News
Achilles Therapeutics to Present at Upcoming Conferences LONDON, June 12, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that the Company will be taking part in the following conferences in June: Mon, Jun. 12, 2023
3 Stocks With 1,000% Upside Potential If you're a risk taker on the lookout for stocks with 1000% upside potential, you'd have to venture into speculative territory. It is difficult to find analyst ratings with such a high upside potential unless catalysts could propel the stock that high. Sun, May. 21, 2023
Is Achilles Therapeutics (ACHL) Outperforming Other Medical Stocks This Year? Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Geron (GERN) have performed compared to their sector so far this year. Thu, Feb. 02, 2023
Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference LONDON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that Dr. Iraj Ali, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 8:15 am PST. The event will be held at the Westin St. Francis Hotel in San Francisco, California. Tue, Dec. 20, 2022
Achilles Therapeutics: The First Full Position In My Tax Loss Selling Basket ACHL has about $4.40 of cash per share on hand, yet it trades below $1. I believe that recent selling is due to tax loss sellers needing to recognize capital loss before the end of the year, and hence their selling is indiscriminate. Sun, Dec. 18, 2022

SEC Filings

SEC Filings
Achilles Therapeutics plc (ACHL) - S-8 SEC Filings 04/04/2024
Achilles Therapeutics plc (ACHL) - 20-F SEC Filings 04/04/2024
Achilles Therapeutics plc (ACHL) - SC 13G/A SEC Filings 03/29/2024
Achilles Therapeutics plc (ACHL) - SC 13G/A SEC Filings 02/14/2024
Achilles Therapeutics plc (ACHL) - SC 13G/A SEC Filings 02/13/2024
Achilles Therapeutics plc (ACHL) - 6-K - Current report SEC Filings 11/13/2023
Achilles Therapeutics plc (ACHL) - 6-K - Current report SEC Filings 09/22/2023
Achilles Therapeutics plc (ACHL) - 6-K - Current report SEC Filings 08/04/2023
Achilles Therapeutics plc (ACHL) - 6-K - Current report SEC Filings 06/29/2023
Achilles Therapeutics plc (ACHL) - 6-K - Current report SEC Filings 05/10/2023
Achilles Therapeutics plc (ACHL) - 6-K - Current report SEC Filings 04/24/2023
Achilles Therapeutics plc (ACHL) - S-8 SEC Filings 03/08/2023
Achilles Therapeutics plc (ACHL) - 20-F SEC Filings 03/07/2023
Achilles Therapeutics plc (ACHL) - SC 13G/A SEC Filings 02/14/2023
Achilles Therapeutics plc (ACHL) - SC 13G/A SEC Filings 02/13/2023
Achilles Therapeutics plc (ACHL) - SC 13D/A SEC Filings 12/30/2022
Achilles Therapeutics plc (ACHL) - SC 13D/A SEC Filings 12/23/2022
Achilles Therapeutics plc (ACHL) - SC 13D/A SEC Filings 12/15/2022
Achilles Therapeutics plc (ACHL) - EFFECT SEC Filings 11/18/2022
Achilles Therapeutics plc (ACHL) - F-3 SEC Filings 11/08/2022
Achilles Therapeutics plc (ACHL) - 6-K - Current report SEC Filings 11/08/2022
Achilles Therapeutics plc (ACHL) - 6-K - Current report SEC Filings 08/09/2022
Achilles Therapeutics plc (ACHL) - SC 13G SEC Filings 07/25/2022
Achilles Therapeutics plc (ACHL) - 6-K - Current report SEC Filings 06/28/2022
Achilles Therapeutics plc (ACHL) - 6-K - Current report SEC Filings 05/26/2022
Achilles Therapeutics plc (ACHL) - 6-K - Current report SEC Filings 05/10/2022
Achilles Therapeutics plc (ACHL) - 6-K - Current report SEC Filings 05/04/2022
Achilles Therapeutics plc (ACHL) - S-8 SEC Filings 03/02/2022
Achilles Therapeutics plc (ACHL) - 20-F SEC Filings 03/01/2022
Achilles Therapeutics plc (ACHL) - SC 13G SEC Filings 02/14/2022
Achilles Therapeutics plc (ACHL) - SC 13G SEC Filings 02/11/2022
Achilles Therapeutics plc (ACHL) - 6-K - Current report SEC Filings 11/09/2021
Achilles Therapeutics plc (ACHL) - 6-K - Current report SEC Filings 08/10/2021
Achilles Therapeutics plc (ACHL) - 6-K - Current report SEC Filings 06/28/2021
Achilles Therapeutics plc (ACHL) - 6-K - Current report SEC Filings 05/26/2021
Achilles Therapeutics plc (ACHL) - 6-K - Current report SEC Filings 05/11/2021
Achilles Therapeutics plc (ACHL) - 6-K - Current report SEC Filings 05/03/2021
Achilles Therapeutics plc (ACHL) - SC 13D SEC Filings 04/16/2021
Achilles Therapeutics plc (ACHL) - SC 13G SEC Filings 04/15/2021
Achilles Therapeutics plc (ACHL) - SEC STAFF LETTER SEC Filings 04/12/2021
Achilles Therapeutics plc (ACHL) - S-8 SEC Filings 04/06/2021
Achilles Therapeutics plc (ACHL) - EFFECT SEC Filings 03/31/2021
Achilles Therapeutics plc (ACHL) - EFFECT SEC Filings 03/31/2021
Achilles Therapeutics plc (ACHL) - 424B4 SEC Filings 03/31/2021
Achilles Therapeutics plc (ACHL) - CERT SEC Filings 03/30/2021
Achilles Therapeutics plc (ACHL) - F-1/A SEC Filings 03/29/2021
Achilles Therapeutics plc (ACHL) - CORRESP SEC Filings 03/29/2021
Achilles Therapeutics plc (ACHL) - 8-A12B SEC Filings 03/29/2021
Achilles Therapeutics plc (ACHL) - UPLOAD SEC Filings 03/26/2021
Achilles Therapeutics plc (ACHL) - CORRESP SEC Filings 03/26/2021
Achilles Therapeutics plc (ACHL) - F-1/A SEC Filings 03/25/2021
Achilles Therapeutics plc (ACHL) - CORRESP SEC Filings 03/25/2021
Achilles Therapeutics plc (ACHL) - UPLOAD SEC Filings 03/11/2021
Achilles Therapeutics plc (ACHL) - F-1/A SEC Filings 03/10/2021
Achilles Therapeutics plc (ACHL) - CORRESP SEC Filings 03/10/2021
Achilles Therapeutics plc (ACHL) - F-1 SEC Filings 03/01/2021
Achilles Therapeutics plc (ACHL) - SEC STAFF LETTER SEC Filings 02/03/2021
Achilles Therapeutics plc (ACHL) - DRS/A SEC Filings 02/02/2021
Achilles Therapeutics plc (ACHL) - DRSLTR SEC Filings 01/08/2021
Achilles Therapeutics plc (ACHL) - DRS/A SEC Filings 01/08/2021
Achilles Therapeutics plc (ACHL) - UPLOAD SEC Filings 12/23/2020
Achilles Therapeutics plc (ACHL) - DRS SEC Filings 11/27/2020

Press Releases

StockPrice Release
Achilles therapeutics reports fourth quarter and year-end 2023 financial results and recent business highlights 04/04/2024
Achilles therapeutics provides interim phase i/iia update on clonal neoantigen reactive t cells in advanced nsclc and melanoma including first patients dosed with enhanced host conditioning 04/04/2024
Achilles therapeutics to present at the 10th annual immuno-oncology 360 conference 02/05/2024
Achilles therapeutics announces publication of nature cancer ‘comment' on strategy for improved neoantigen immunogenicity prediction 12/18/2023
Achilles therapeutics reports third quarter 2023 financial results and recent highlights 11/13/2023
Achilles therapeutics receives nasdaq deficiency notice regarding minimum bid price requirement 09/22/2023
Achilles therapeutics reports second quarter 2023 financial results and recent business highlights 08/04/2023
Achilles therapeutics to present at upcoming conferences 06/12/2023
Achilles therapeutics reports first quarter 2023 financial results and recent business highlights 05/10/2023
Achilles therapeutics' new immunogenicity prediction application of its ai-powered peleus™ platform uniquely identifies the most potent t cell antigens 05/10/2023
Achilles therapeutics receives nasdaq deficiency notice regarding minimum bid price requirement 04/25/2023
Achilles therapeutics announces grant of us patent covering the treatment of patients with an immunotherapy targeting neoantigens based on tumor hla status 04/25/2023
Achilles therapeutics reports fourth quarter and year-end 2022 financial results and recent business highlights 03/07/2023
Achilles therapeutics to present at the 41st annual j.p. morgan healthcare conference 12/20/2022
Achilles therapeutics presents encouraging phase i/iia update on clonal neoantigen reactive t cells in advanced nsclc and melanoma at esmo io congress 2022 12/06/2022
Achilles therapeutics to present early proof of concept of safety and clinical activity of clonal neoantigen reactive t cells at the esmo immuno-oncology annual congress 2022 11/30/2022
Achilles therapeutics announces grant of us patent on immunotherapies targeting clonal neoantigens identified using proprietary method 11/22/2022
Achilles therapeutics reports third quarter 2022 financial results and recent business highlights 11/08/2022
Achilles therapeutics co-founder professor charles swanton to participate in expert roundtable highlighting pivotal nature of neoantigens as targets in cancer cell therapy 10/06/2022
Achilles therapeutics reports second quarter 2022 financial results and recent business highlights 08/09/2022
Achilles therapeutics to lead horizon europe-funded consortium to advance personalized cell therapy manufacturing 07/21/2022
Achilles therapeutics appoints james taylor as chief business officer and cassian yee, md to scientific advisory board 06/30/2022
Achilles therapeutics recognized with the 2022 ping innovation award 06/21/2022
Achilles therapeutics reports first quarter 2022 financial results and recent business highlights 05/10/2022
Achilles therapeutics doses first patient with higher-dose cnet in phase i/iia chiron trial in advanced nsclc and initiates enrollment in cohort b of the thetis trial (cnet + pd-1 checkpoint inhibitor) in metastatic malignant melanoma 05/09/2022
Achilles therapeutics appoints bernhard ehmer to board of directors 05/04/2022
Achilles therapeutics to present at upcoming conferences 05/03/2022
Achilles therapeutics announces manufacturing expansion in the uk and partnership for manufacturing in the us 04/12/2022
Achilles therapeutics to present at upcoming conferences 04/05/2022
Achilles therapeutics to host kol webcast to highlight tracerx study presentations from the 2022 aacr annual meeting 04/04/2022
Achilles therapeutics to present at the 32nd annual oppenheimer healthcare conference 03/08/2022
Achilles therapeutics reports fourth quarter and year-end 2021 financial results and recent business highlights 03/01/2022
Achilles therapeutics strengthens scientific advisory board with appointment of alena gros, ph.d. and ben creelan, m.d. 02/07/2022
Achilles therapeutics provides business update and outlook for 2022 01/13/2022
Achilles therapeutics to present at the 40th annual j.p. morgan healthcare conference 12/21/2021
Achilles therapeutics added to the nasdaq biotechnology index 12/20/2021
Achilles therapeutics presents positive data at esmo i-o congress 2021 on high-dose manufacturing process for precision t cell therapies targeting clonal neoantigens 12/09/2021
Achilles therapeutics presents data at the society for immunotherapy of cancer (sitc) annual meeting demonstrating the ability to detect, quantify and track patient-specific cnet and significant increase in cnet dose from velos™ process 2 manufacturing 11/12/2021
Secarna pharmaceuticals and achilles therapeutics sign research, option and license agreement to develop optimized t cell therapies 11/10/2021
Achilles therapeutics reports third quarter 2021 financial results and recent business highlights 11/09/2021
Achilles therapeutics presents data at the 2021 european society for gene and cell therapy (esgct) congress demonstrating its proprietary manufacturing process can generate potent, personalized anti-cancer cell therapy candidates in multiple solid tumor types 10/22/2021
Achilles therapeutics to present at upcoming scientific congresses 10/01/2021
Achilles therapeutics to present at upcoming investor conferences 09/02/2021
Achilles therapeutics announces grant of us and european patents 08/25/2021
Achilles therapeutics enrolls first us patient in ongoing phase i/iia study in advanced non-small cell lung cancer 07/01/2021
Achilles therapeutics reports first quarter 2021 financial results and recent business highlights 05/11/2021
Achilles therapeutics to present at the bofa securities 2021 virtual healthcare conference 05/05/2021
Achilles therapeutics appoints julie o'neill to board of directors and markwin velders, ph.d. joins scientific advisory board 05/03/2021
Forbion announces final close of forbion growth opportunities fund i at eur 360 million (usd 428 million) 04/20/2021
Achilles therapeutics demonstrates cnet product characterization and post-infusion tracking in a patient case study at the american association for cancer research (aacr) 2021 annual meeting 04/10/2021
Achilles therapeutics announces closing of $175.5 million initial public offering 04/06/2021
Achilles therapeutics announces pricing of initial public offering 03/30/2021
A.m. best affirms credit ratings of axis specialty limited and axis capital holdings limited 11/03/2016
A.m. best affirms ratings of markel corporation and its subsidiaries 07/01/2016
A.m. best removes from under review and affirms ratings of axis capital holdings limited and its subsidiaries 08/04/2015
A.m. best places the ratings of axis capital holdings limited and its subsidiaries under review with negative implications 01/26/2015
A.m. best affirms ratings of axis specialty limited and axis capital holdings limited 09/30/2014
A.m. best ratings upgrades ratings of axis capital holdings limited 09/25/2013
A.m. best affirms ratings of axis capital holdings limited and its subsidiaries 09/21/2012
A.m. best revises outlook to positive for axis specialty limited and its operating affiliates 11/22/2011

More Headlines

News
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022 - Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT monotherapy - 11/30/2022
What Makes Achilles Therapeutics PLC Sponsored ADR (ACHL) a New Buy Stock Achilles Therapeutics PLC Sponsored ADR (ACHL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. 11/01/2022
Achilles Therapeutics to Present at Upcoming Conferences LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that the Company will be taking part in the following conferences in May. 05/03/2022
Achilles Therapeutics to Present at Upcoming Conferences LONDON, April 05, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that management will be taking part in the following conferences in April. 04/05/2022
Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting - Webcast will feature Professor Charles Swanton, TRACERx Chief Investigator and Achilles co-founder - 04/04/2022
Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference LONDON, March 08, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its participation in the 32nd Annual Oppenheimer Healthcare Conference taking place virtually March 15 - 17, 2022. Iraj Ali, Chief Executive Officer, will present an overview of the company and pipeline on Tuesday, March 15, 2022, at 8:00 am ET / 12:00 pm UK. 03/08/2022
Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference LONDON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that Iraj Ali, Chief Executive Officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022, at 8:15 a.m. ET. 12/21/2021
Achilles Therapeutics plc (ACHL) CEO Iraj Ali on SITC & Corporate Update Call (Transcript) Achilles Therapeutics plc (ACHL) CEO Iraj Ali on SITC & Corporate Update Call (Transcript) 11/12/2021
Achilles Therapeutics to Present at Upcoming Scientific Congresses LONDON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, will present an oral presentation at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress being held in a virtual format from October 19-22, 2021, and two posters at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting being held in a hybrid format from November 10-14, 2021 online and in person in Washington, DC. 10/01/2021
Achilles Therapeutics to Present at Upcoming Investor Conferences LONDON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that management will present at the following investor conferences in September. 09/02/2021
Achilles Therapeutics Announces Grant of US and European Patents LONDON, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that US patent US 11,098,121 and European patent EP3347039B have been granted. The patents cover a method of identifying cancer patients that are likely to respond to a checkpoint inhibitor (CPI) by determining the total number of clonal neoantigens or the ratio of clonal to subclonal neoantigens in patients' cancer cells. Clonal neoantigens are neoantigens present on all tumor cells and absent from healthy tissue. 08/25/2021
Achilles Therapeutics Appoints Julie O'Neill to Board of Directors and Markwin Velders, Ph.D. joins Scientific Advisory Board LONDON, United Kingdom, May 03, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announces the appointment of Julie O'Neill as a Non-Executive Director to the Board and Markwin Velders, Ph.D. to its Scientific Advisory Board (SAB). Both individuals come to Achilles with strong track records of experience in cell therapy and cell therapy manufacturing. 05/03/2021
Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study at the American Association for Cancer Research (AACR) 2021 Annual Meeting LONDON, April 10, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today presented a patient case study from the Company's ongoing Phase I/IIa THETIS trial in metastatic or recurrent melanoma at the American Association for Cancer Research (AACR) Annual Meeting 2021. Through a comprehensive translational research program, data from Patient T-05 offer insight into the in vivo dynamics of clonal neoantigen T cells (cNeT) post-dosing and the potential to develop a potency-based release assay. 04/10/2021
Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering LONDON, April 06, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the closing of its previously announced initial public offering in the United States of 9,750,000 American Depositary Shares (“ADSs”) representing 9,750,000 ordinary shares, at an initial public offering price of $18.00 per ADS. The gross proceeds to Achilles from the offering were approximately $175.5 million. All ADSs sold in the offering were offered by Achilles. 04/06/2021
U.S. IPO Weekly Recap: The IPO Market Slows With 6 IPOs In The Shortened Holiday Week The IPO market pumped the brakes in the shortened holiday week, with six IPOs raising $1.9 billion and just two SPACs raising $300 million. Two blank check companies went public this past week. 04/02/2021
Achilles Therapeutics and Coursera Open for Trading Today Achilles Therapeutics, a biotech developing T-cell therapies for cancer, and Coursera, an educational technology company, are making their public stock market debut. 03/31/2021
UK-based Achilles Therapeutics unveils US$175.5mln IPO at Nasdaq debut Achilles Therapeutics plc (NASDAQ: ACHL) announced the pricing of its IPO on the Nasdaq that will raise US$175.5mln (£127.8mln). The clinical-stage biopharma, which is developing precision T cell therapies to treat solid tumours, will place 9.7mln American depositary shares (ADSs) at US$18 a pop. 03/31/2021
Achilles Therapeutics Announces Pricing of Initial Public Offering LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the pricing of its initial public offering in the United States of 9,750,000 American Depositary Shares (“ADSs”) representing 9,750,000 ordinary shares at an initial public offering price of $18.00 per ADS for total gross proceeds of $175.5 million. All ADSs sold in the offering are being offered by Achilles. The ADSs are expected to begin trading on The Nasdaq Global Select Market on March 31, 2021 under the ticker symbol “ACHL.” In addition, Achilles has granted the underwriters a 30-day option to purchase up to an additional 1,462,500 ADSs at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on April 6, 2021, subject to customary closing conditions. 03/30/2021

Unlock

ACHL Ratings Summary

ACHL Quant Ranking

Is Achilles Therapeutics plc (ACHL) a buy, sell, or hold?

What is Achilles Therapeutics plc's stock price?

Is Achilles Therapeutics plc (ACHL) overvalued or undervalued?

Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022

What Makes Achilles Therapeutics PLC Sponsored ADR (ACHL) a New Buy Stock

Achilles Therapeutics to Present at Upcoming Conferences

Achilles Therapeutics to Present at Upcoming Conferences

Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting

Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference

Achilles Therapeutics plc (ACHL) CEO Iraj Ali on SITC & Corporate Update Call (Transcript)

Achilles Therapeutics to Present at Upcoming Scientific Congresses

Achilles Therapeutics to Present at Upcoming Investor Conferences

Achilles Therapeutics Announces Grant of US and European Patents

Achilles Therapeutics Appoints Julie O'Neill to Board of Directors and Markwin Velders, Ph.D. joins Scientific Advisory Board

Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study at the American Association for Cancer Research (AACR) 2021 Annual Meeting

Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering

U.S. IPO Weekly Recap: The IPO Market Slows With 6 IPOs In The Shortened Holiday Week

Achilles Therapeutics and Coursera Open for Trading Today

UK-based Achilles Therapeutics unveils US$175.5mln IPO at Nasdaq debut

Achilles Therapeutics Announces Pricing of Initial Public Offering